Predictive factors of survival outcomes in first‐line therapy for metastatic castration‐resistant prostate cancer
Author:
Affiliation:
1. Department of Urology Graduate School of Medical Sciences Kyushu University Japan
2. Department of Urology Harasanshin Hospital Fukuoka Japan
Publisher
Wiley
Subject
Urology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/iju.14702
Reference18 articles.
1. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone‐sensitive prostate cancer;Shiota M;Int. J. Urol.,2016
2. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock IF;N. Engl. J. Med.,2004
3. Abiraterone and increased survival in metastatic prostate cancer;Bono JS;N. Engl. J. Med.,2011
4. Abiraterone in metastatic prostate cancer without previous chemotherapy;Ryan CJ;N. Engl. J. Med.,2013
5. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher HI;N. Engl. J. Med.,2012
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Impact of Novel Agents on Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer;Anticancer Research;2024-06-26
2. GLIDR promotes the aggressiveness progression of prostate cancer cells by sponging miR-128–3p;Pathology - Research and Practice;2023-02
3. Effects of apalutamide dose reduction on skin‐related adverse events in patients with advanced prostate cancer: A multicenter retrospective study;The Prostate;2022-10-31
4. Humoral response after SARS-CoV-2 mRNA vaccination in patients with prostate cancer using steroids;Urologic Oncology: Seminars and Original Investigations;2022-10
5. Clinical Outcome and Prognostic Variables of Second-line Therapy for Patients With Castration-resistant Prostate Cancer After Failure of First-line Androgen Receptor Axis-targeted Therapy;Anticancer Research;2022-03-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3